LEGN Stock Plunges 15% After Sudden CEO Exit — But Analyst Reiterates Optimism In Company’s Under-Development Lymphoma Asset
Shares of Legend Biotech (LEGN) plunged about 15% on Monday after the cell therapy company announced a sudden CEO transition, and RBC Capital slashed its price target on the stock.Legend said on Monday that Ying Huang stepped down as chief executive officer and board member effective July 24.“Huang…